13-valent pneumococcal conjugate vaccine + 13-valent pneumococcal conjugate vaccine

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Pneumococcal Vaccines

Conditions

Pneumococcal Vaccines

Trial Timeline

Jan 1, 2014 → Sep 1, 2014

NCT ID

NCT01964716

About 13-valent pneumococcal conjugate vaccine + 13-valent pneumococcal conjugate vaccine

13-valent pneumococcal conjugate vaccine + 13-valent pneumococcal conjugate vaccine is a phase 3 stage product being developed by Pfizer for Pneumococcal Vaccines. The current trial status is completed. This product is registered under clinical trial identifier NCT01964716. Target conditions include Pneumococcal Vaccines.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01964716	Phase 3	Completed	Jan 1, 2014	Sep 1, 2014	Pneumococcal Vaccines
NCT01193335	Approved	Completed	Oct 1, 2010	Jan 1, 2014	13-valent Pneumococcal Vaccine
NCT00824850	Phase 2	Completed	Jan 1, 2010	Sep 1, 2010	Pneumococcal Conjugate Vaccine

Competing Products

20 competing products in Pneumococcal Vaccines

See all competitors

Product	Company	Stage	Hype Score
V116 + PPSV23	Merck	Phase 3	77
V114 + QIV + Matching Placebo for V114	Merck	Phase 3	77
V114 + Prevnar 13™ + PNEUMOVAX™23	Merck	Phase 3	77
V114 Lot 1 + V114 Lot 2 + Prevnar 13™	Merck	Phase 2	52
PNEUMOVAX™ 23	Merck	Approved	85
Pneumococcal Vaccine, Polyvalent (23-valent)	Merck	Phase 3	77
V114 + Prevnar 13™ + PNEUMOVAX™23	Merck	Phase 3	77
V114 + Prevnar 13®	Merck	Phase 3	77
V114 Medium Dose + V114 High Dose + V114 Medium Dose with Alternative Carrier Protein + V114 High Dose with Alternative Carrier Protein + Prevnar 13™	Merck	Phase 1/2	41
V116 + PPSV23	Merck	Phase 3	77
V114	Merck	Phase 3	77
Prevnar 13™ + V114 + RotaTeq™ + Pentacel™ + RECOMBIVAX HB™ + HIBERIX™ + M-M-R™ II + VARIVAX™	Merck	Phase 3	77
V114 + Prevnar 13®	Merck	Phase 3	77
Pneumococcal Conjugate Vaccine (V114) + PNEUMOVAX® 23 + PREVNAR 13®	Merck	Phase 2	52
V114-A + V114-B + Prevnar 13®	Merck	Phase 2	52
V116 + Pneumovax™23	Merck	Phase 1/2	41
V114 + Prevnar 13™	Merck	Phase 3	77
V114 + Prevnar 13™	Merck	Phase 2	52
Simultaneous administration of Pneumovax NP® and Fluvic HA syringe® + Sequential administration of Pneumovax NP® and Fluvic HA syringe®	Merck	Approved	85
21-valent pneumococcal conjugate vaccine	Merck	Approved	85

Other Products from Pfizer